2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof

1. A compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof,

wherein

L is a bond, —(C(R 3b ) 2 ) n —, —N(R 1 )—(C(R 3b ) 2 ) n —, —O—(C(R 3b ) 2 ) n —, —S(═O) m — or —C(═O)—(C(R 3b ) 2 ) n —;

ring A is

and wherein when is a double bond, T is X,

when is a single bond, T is X 6 ,

R is H, R 13 , —(C(R 3b ) 2 ) n —N(R 1a )—C(═O)—(C(R 3b ) 2 ) n —R 13 or —(CH 2 ) n —C(═O)—N(R 1a )—(C(R 3b ) 2 ) n —R 13 ;

R 13 is H, C 3-9 cycloalkyl, heteroaryl, heterocyclyl, spiro heterobicyclyl, bridged heterobicyclyl or fused heterobicyclyl;

each X 7 , X 5 and X 6 is independently —C(R 3a ) 2 —, —N(R 2 )—, —O—, —S(═O) m — or —C(═O)—;

each X, X 1 , X 2 , X 3 and X 4 is independently CR 3a or N;

each n is independently 0, 1, 2, 3, or 4;

each n1 is independently 1, 2, or 3;

each m is independently 0, 1, or 2;

each R 1a , R 1 and R 2 is independently H, C 1-4 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, (R 4 ) 2 N—(C(R 3 ) 2 ) n —, HO—(C(R 3 ) 2 ) n —C(═O)—, N(R 4 ) 2 —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —C(═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, heterocyclyl, heteroaryl, C 3-9 cycloalkyl or C 1-4 alkyl;

each R 3a , R 3b and R 3 is independently H, F, Cl, Br, C 1-4 alkyl, hydroxy, carboxy, amino, heterocyclyl, heteroaryl, C 3-9 cycloalkyl, C 1-4 haloalkyl, H—(CH 2 ) n —O—(CH 2 ) n —, N(R 4 ) 2 —C(═O)—, H—(CH 2 ) n —SO 2 —(CH 2 ) n —, H—O—(CH 2 ) n —C(═O)—(CH 2 ) n —, H—(CH 2 ) n —C(═O)—(CH 2 ) n — or N(R 4 ) 2 —(CH 2 ) n —;

each R 4 is independently H, C 1-4 alkyl, hydroxy, carboxy, amino, C 1-4 alkoxy, amino-C 1-4 -alkyl, NH 2 —C(═O)—, heterocyclyl, heteroaryl, C 3-9 cycloalkyl, C 1-4 haloalkyl or C 1-4 alkylamino;

each moiety represented by A is independently and optionally substituted with one, two, three or four substituents independently selected from H, C 1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 alkylamino, amino-C 1-4 -alkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, (R 4 ) 2 N—(C(R 3 ) 2 ) n —, HO—(C(R 3 ) 2 ) n —C(═O)—, N(R 4 ) 2 —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —C(═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, cyano and nitro;

each alkyl, haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, N(R 4 ) 2 —C(═O)—, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, —(C(R 3 ) 2 ) n —N(R 4 ) 2 , HO—(C(R 3 ) 2 ) n —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —C(═O)—, spiro heterobicyclyl, bridged heterobicyclyl, fused heterobicyclyl, heterocyclyl, cycloalkyl, heteroaryl and H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n — described in R, R 1 , R 1a , R 2 and/or R 13 is optionally and independently substituted with one, two, three or four independent R 5 ;

each R 5 is independently H, oxo, C 1-6 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 alkylamino, amino-C 1-4 -alkyl, N(R 4 ) 2 —C(═O)—, CN—(C(R 3 ) 2 ) n —C(═O)—, C 1-6 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n1 —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, cyano, heterocyclyl, C 3-9 cycloalkyl, heteroaryl or nitro;

each alkyl, alkoxy, alkylamino, aminoalkyl, N(R 4 ) 2 —C(═O)—, CN—(C(R 3 ) 2 ) n —C(═O)—, haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n1 —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, heterocyclyl, cycloalkyl and heteroaryl described in R 5 is independently and optionally substituted with one, two, three or four independent R 6 ; and

each R 6 is independently H, oxo, C 1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 alkylamino, amino-C 1-4 -alkyl, N(R 4 ) 2 —C(═O)—, CN—(C(R 3 ) 2 ) n —C(═O)—, C 1-4 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n1 —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, cyano, heterocyclyl, C 3-9 cycloalkyl, heteroaryl or nitro,

wherein each of heteroaryl, heterocyclyl, spiro heterobicyclyl, bridged heterobicyclyl and fused heterobicyclyl has 1-3 ring members independently selected from N, O, P and S,

wherein heteroaryl is 5-6 membered monocyclic ring, 7-10 membered bicyclic ring or 10-15 membered tricyclic ring; and

wherein heterocyclyl is a saturated or partially unsaturated monocyclic ring having 3-7 ring members or a bicyclic ring having 7-10 ring members.

2. The compound of claim 1 having Formula (II) or Formula (III) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof,

wherein

L is a bond, —(CH 2 ) n —, —N(R 1 )—, —O—, —S— or —C(═O)—.

3. The compound of claim 1 , wherein

R 13 is H,

and wherein each Y, Y 1 , Y 7 and Y 2 is independently —C(R 3c ) 2 —, —N(R 2b )—, —O—, —S(═O) m — or —C(═O)—;

each Y 3 , Y 4 and Y 5 is independently CR 3c or N; and

each R 2b is independently H, C 1-4 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, (R 4 ) 2 N—(C(R 3 ) 2 ) n —, HO—(C(R 3 ) 2 ) n —C(═O)—, N(R 4 ) 2 —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —C(═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n — or C 1-4 alkyl;

each R 3c is independently H, F, Cl, Br, C 1-4 alkyl, hydroxy, carboxy, amino, C 1-4 haloalkyl, H—(CH 2 ) n —O—(CH 2 ) n —, N(R 4 ) 2 —C(═O)—, H—(CH 2 ) n —SO 2 —(CH 2 ) n —, H—O—(CH 2 ) n —C(═O)—(CH 2 ) n —, H—(CH 2 ) n —C(═O)—(CH 2 ) n — or N(R 4 ) 2 —(CH 2 ) n —;

each e, r, f and g is independently 0, 1, 2, or 3.

4. The compound of claim 1 , wherein

R 13 is cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, H,

and wherein each moiety represented by R 13 is independently and optionally substituted with one, two, three or four independent R 5 .

5. The compound of claim 1 , wherein

ring A is

each moiety represented by A is independently and optionally substituted with one, two, three or four substituents independently selected from H, C 1-4 alkyl, F, Cl, Br, amino, hydroxy, carboxy, C 1-4 alkoxy, C 1-4 haloalkyl, C 1-4 alkylamino, amino-C 1-4 -alkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, (R 4 ) 2 N—(C(R 3 ) 2 ) n —, HO—(C(R 3 ) 2 ) n —C(═O)—, N(R 4 ) 2 —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —C(═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, cyano and nitro.

6. The compound of claim 1 , wherein

each R 3a , R 3b and R 3 is independently H, F, Cl, Br, hydroxy, carboxy, amino, trifluoromethyl, methyl, ethyl, propyl, butyl, cyclopropyl, cyclohexyl, cyclopentyl, H—(CH 2 ) n —O—(CH 2 ) n —, N(R 4 ) 2 —C(═O)—, H—(CH 2 ) n —SO 2 —(CH 2 ) n —, H—O—(CH 2 ) n —C(═O)—(CH 2 ) n — or N(R 4 ) 2 —(CH 2 ) n —; and

each R 4 is independently H, hydroxy, carboxy, amino, methoxy, aminomethyl, aminoethyl, NH 2 —C(═O)—, trifluoromethyl, 2,2-difluoroethyl, methyl, ethyl, propyl or butyl.

7. The compound of claim 1 , wherein

each R 1a , R 1 and R 2 is independently H, 3,3,3-trifluoropropyl, trifluoromethyl, 1,1-difluoroethyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, (R 4 ) 2 N—(C(R 3 ) 2 ) n —, HO—(C(R 3 ) 2 ) n —C(═O)—, N(R 4 ) 2 —C(═O)—, HO—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, CN—(C(R 3 ) 2 ) n —(C═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —,

methyl, ethyl, propyl or butyl;

each R 5 is independently H, oxo, methyl, ethyl, propyl, butyl, F, Cl, Br, amino, hydroxy, carboxy, methoxy, C 1-4 alkylamino, amino-C 1-4 -alkyl, N(R 4 ) 2 —C(═O)—, CN—(C(R 3 ) 2 ) n —C(═O)—, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —,

C 1-4 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n1 —C(═O)—(C(R 3 ) 2 ) n —, cyano, cyclopropyl, cyclohexyl, cyclopentyl or nitro; and

each R 6 is independently H, oxo, methyl, ethyl, propyl, butyl, F, Cl, Br, amino, hydroxy, carboxy, methoxy, C 1-4 alkylamino, amino-C 1-4 -alkyl, N(R 4 ) 2 —C(═O)—, CN—(C(R 3 ) 2 ) n —C(═O)—, C 1-4 haloalkyl, H—(C(R 3 ) 2 ) n —O—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—C(═O)—C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —SO 2 —(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n1 —C(═O)—(C(R 3 ) 2 ) n —, H—(C(R 3 ) 2 ) n —O—(C(R 3 ) 2 ) n —, cyano, heterocyclyl, C 3-6 cycloalkyl or nitro.

8. The compound of claim 1 having one of the following structures:

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the compound of claim 1 , and at least one of pharmaceutically acceptable carriers, excipients, diluents, adjuvants, vehicles.

10. The pharmaceutical composition of claim 9 further comprising an additional therapeutic agent; wherein the additional therapeutic agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory reagent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK4/6 inhibitor, an ABL inhibitor, an ABL/Scrinhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, an FLT3 inhibitor, an FLT3-ITD inhibitor or a combination thereof.

11. The pharmaceutical composition of claim 10 , wherein the additional therapeutic agent is chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cis-platinum, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbozine, methotrexate, fluorouracil, cytosine arabinoside, gemcitabine, purinethol, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, pharmorubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonadorelin analogue, megestrol acetate, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon α, calcium folinate, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, zelboraf, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, cabozantinib, ponatinib, midostaurin, pacritinib, quizartinib, gilteritinib, AKN-028, AT-9283, crenolanib, ENMD-2076, famitinib, dovitinib, PLX-3397, palbociclib, abemaciclib, ribociclib, rigosertib sodium, selinexor, roniciclib, AT-7519, seliciclib, alvocidib or a combination thereof.

12. A method of treating a disorder or disease in a human comprising administering a therapeutically effective amount of the compound of claim 1 to the human, wherein the disorder or disease is breast cancer caused by a change in cyclin-dependent kinase, wherein the cyclin-dependent kinase is CDK4 or CDK6.

13. A drug combination comprising the compound of claim 1 and one or more other activity agents used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the other activity agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK 4/6 kinase inhibitor, an ABL inhibitor, an ABL/Scr inhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, a FLT3 inhibitor, a FLT3-ITD inhibitor or a combination thereof.

14. A method of treating a disorder or disease in a human comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 9 to the human, wherein the disorder or disease is breast cancer caused by a change in cyclin-dependent kinase, wherein the cyclin-dependent kinase is CDK4 or CDK6.

15. A drug combination comprising the pharmaceutical composition of claim 9 and one or more other activity agents used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the other activity agent is a chemotherapeutic drug, an antiproliferative agent, an immunosuppressor, an immunologic stimulant, an anti-inflammatory agent, an agent for treating atherosclerosis, an agent for treating pulmonary fibrosis, a CDK 4/6 kinase inhibitor, an ABL inhibitor, an ABL/Scr inhibitor, an aurora kinase inhibitor, a non-ATP competitive inhibitor of BCR-ABL, a c-KIT mutation inhibitor, an RET inhibitor, a PDGFR inhibitor, a VEGFR inhibitor, a CSF1R inhibitor, a FLT3 inhibitor, a FLT3-ITD inhibitor or a combination thereof.